{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:36:35Z","timestamp":1784900195711,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>STUDY QUESTION<\/jats:title><jats:p>Are serum levels of anti-M\u00fcllerian hormone (AMH) normal in patients with functional hypothalamic anovulation (FHA)?<\/jats:p><\/jats:sec><jats:sec><jats:title>SUMMARY ANSWER<\/jats:title><jats:p>Our study confirms that in the general FHA population, serum AMH levels are not decreased, but if patients with polycystic ovarian morphology (PCOM) are excluded, levels become significantly lower, as in other situations of gonadotropic insufficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>WHAT IS KNOWN ALREADY<\/jats:title><jats:p>In most situations of low LH (physiological, pharmacological or pathological), serum AMH levels are low. However, paradoxically, many publications have reported normal or even increased serum AMH levels in FHA patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title><jats:p>Retrospective observational study conducted in an academic centre. The data concerning the study population was collected between 2006 and 2015 from a database including clinical, biological and ultrasound information.<\/jats:p><\/jats:sec><jats:sec><jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title><jats:p>A total of 45 FHA patients were compared to 37 controls matched based on age and body mass index (BMI). Serum LH, FSH, androstenedione, total testosterone, prolactin and AMH levels were measured by immunoassay. We defined PCOM with strict criteria: a follicle number per ovary (FNPO) \u2265 12 or \u2265 19 per ovary, depending on the date on which the assessment was carried out and the ultrasound device. An AMH level \u2265 35\u2009pmol\/l could be a substitute for an excess FNPO. Controls meeting these criteria were not included in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title><jats:p>There was no significant difference in the ranges of AMH levels between FHA and controls. Using strict criteria to define PCOM status, 46.7% of FHA patients had PCOM. After excluding these patients, the levels of AMH were significantly lower (P\u2009&amp;lt; 0.002) in FHA patients compared to controls. Within the FHA group, patients with PCOM had significantly higher ranks of AMH levels and BMI than those without PCOM. However, within the PCOM+ subgroup, the ranks of LH, FSH and A levels were still lower than in controls (P \u2009&amp;lt;\u20090.0001, &amp;lt;0.002 and &amp;lt;0.05, respectively). The positive correlation between AMH and LH was significant in the controls but not in the FHA group. However, in the FHA PCOM+, there was a strong positive correlation between BMI and LH.<\/jats:p><\/jats:sec><jats:sec><jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title><jats:p>This is a retrospective study; our controls did not represent the general population as they were recruited in an ART centre; we used a modified classification for PCOM using follicle count and\/or AMH level with in-house thresholds to define the follicle excess; the AMH assay used is no longer commercially available.<\/jats:p><\/jats:sec><jats:sec><jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title><jats:p>Besides biasing the results of AMH assay in FHA patients, the presence of PCOM in FHA patients despite low gonadotropin and androgen levels raises the issue of epigenetically acquired amplification of androgen and\/or FSH sensitivity within granulosa cells from polycystic ovaries. In terms of clinical practice, it seems important not to diagnose a low ovarian reserve in FHA patients too quickly on the basis of a decreased AMH level alone. On the contrary, a high AMH level in the context of a menstrual disorder and PCOM should not lead to a misdiagnosis of polycystic ovary syndrome (PCOS) if the basal LH is low.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title><jats:p>None<\/jats:p><\/jats:sec><jats:sec><jats:title>TRIAL REGISTRATION NUMBER<\/jats:title><jats:p>N\/A<\/jats:p><\/jats:sec>","DOI":"10.1093\/humrep\/deab024","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T20:15:24Z","timestamp":1610914524000},"page":"1043-1051","source":"Crossref","is-referenced-by-count":31,"title":["Revisiting the serum level of anti-M\u00fcllerian hormone in patients with functional hypothalamic anovulation"],"prefix":"10.1093","volume":"36","author":[{"given":"Sarah","family":"Makolle","sequence":"first","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Gyn\u00e9cologie Endocrinienne, Service de Gyn\u00e9cologie M\u00e9dicale, Orthog\u00e9nie et Sexologie, H\u00f4pital Jeanne de Flandre, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Catteau-Jonard","sequence":"additional","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Gyn\u00e9cologie Endocrinienne, Service de Gyn\u00e9cologie M\u00e9dicale, Orthog\u00e9nie et Sexologie, H\u00f4pital Jeanne de Flandre, Lille, France"},{"name":"Inserm, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean- Pierre Aubert Research Centre, Lille 59945, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Robin","sequence":"additional","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Gyn\u00e9cologie Endocrinienne, Service de Gyn\u00e9cologie M\u00e9dicale, Orthog\u00e9nie et Sexologie, H\u00f4pital Jeanne de Flandre, Lille, France"},{"name":"Lille University, EA 4308 \u2018Gametogenesis and Gamete Quality\u2019, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Dewailly","sequence":"additional","affiliation":[{"name":"Inserm, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean- Pierre Aubert Research Centre, Lille 59945, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"key":"2021031813501280000_deab024-B1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/humupd\/dmi013","article-title":"Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?","volume":"11","author":"Abbott","year":"2005","journal-title":"Hum Reprod Update"},{"key":"2021031813501280000_deab024-B2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/oxfordjournals.humrep.a137668","article-title":"Implications of ultrasonically diagnosed polycystic ovaries. I. Correlations with basal hormonal profiles","volume":"7","author":"Abdel Gadir","year":"1992","journal-title":"Hum Reprod"},{"key":"2021031813501280000_deab024-B3","doi-asserted-by":"crossref","first-page":"dgaa116","DOI":"10.1210\/clinem\/dgaa116","article-title":"Anti-M\u00fcllerian hormone and ovarian morphology in women with Hypothalamic Hypogonadism","volume":"105","author":"Alemyar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2021031813501280000_deab024-B5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.rbmo.2012.09.001","article-title":"Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception","volume":"25","author":"Bentzen","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2021031813501280000_deab024-B6","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1210\/jc.2016-3799","article-title":"Anti-M\u00fcllerian hormone and ovarian morphology in women with isolated hypogonadotropic hypogonadism\/Kallmann syndrome: effects of recombinant human FSH","volume":"102","author":"Bry-Gauillard","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2021031813501280000_deab024-B7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ando.2010.02.024","article-title":"Congenital hypogonadotropic hypogonadism in females: Clinical spectrum, evaluation and genetics","volume":"71","author":"Bry-Gauillard","year":"2010","journal-title":"Ann Endocrinol"},{"key":"2021031813501280000_deab024-B9","doi-asserted-by":"crossref","first-page":"10055","DOI":"10.1038\/ncomms10055","article-title":"Novel role for anti-M\u00fcllerian hormone in the regulation of GnRH neuron excitability and hormone secretion","volume":"7","author":"Cimino","year":"2016","journal-title":"Nat Commun"},{"key":"2021031813501280000_deab024-B10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2265.1992.tb02296.x","article-title":"How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?","volume":"37","author":"Clayton","year":"1992","journal-title":"Clin Endocrinol"},{"key":"2021031813501280000_deab024-B11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2265.1999.00649.x","article-title":"Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin","volume":"50","author":"Couzinet","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021031813501280000_deab024-B12","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/humrep\/der297","article-title":"Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries","volume":"26","author":"Dewailly","year":"2011","journal-title":"Hum Reprod"},{"key":"2021031813501280000_deab024-B13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/humupd\/dmt061","article-title":"Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2021031813501280000_deab024-B14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/humupd\/dmw027","article-title":"Interactions between androgens, FSH, anti-M\u00fcllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary","volume":"22","author":"Dewailly","year":"2016","journal-title":"Hum Reprod Update"},{"key":"2021031813501280000_deab024-B15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/09513590903247824","article-title":"Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women","volume":"26","author":"Duijkers","year":"2010","journal-title":"Gynecol Endocrinol off J Int Soc Gynecol Endocrinol"},{"key":"2021031813501280000_deab024-B16","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1210\/endo.142.11.8486","article-title":"Anti-M\u00fcllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary","volume":"142","author":"Durlinger","year":"2001","journal-title":"Endocrinology"},{"key":"2021031813501280000_deab024-B17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1479-828X.1994.tb01041.x","article-title":"The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women","volume":"34","author":"Farquhar","year":"1994","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2021031813501280000_deab024-B19","first-page":"279","article-title":"Ultrasonographic study of ovaries of 19 women with weight loss-related hypothalamic oligo-amenorrhea","volume":"42","author":"Futterweit","year":"1988","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"2021031813501280000_deab024-B20","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jc.2010-0202","article-title":"The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance","volume":"95","author":"Johnstone","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2021031813501280000_deab024-B21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/humrep\/deh560","article-title":"The ovarian markers of the FSH insufficiency in functional hypothalamic amenorrhea","volume":"20","author":"Jonard","year":"2005","journal-title":"Hum Reprod"},{"key":"2021031813501280000_deab024-B22","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/humrep\/dei159","article-title":"Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries","volume":"20","author":"Jonard","year":"2005","journal-title":"Hum Reprod"},{"key":"2021031813501280000_deab024-B23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.fertnstert.2012.11.034","article-title":"Antim\u00fcllerian hormone levels decrease in women using combined contraception independently of administration route","volume":"99","author":"Kallio","year":"2013","journal-title":"Fertil Steril"},{"key":"2021031813501280000_deab024-B24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1600-0412.1999.780212.x","article-title":"The prevalence of polycystic ovaries in healthy women","volume":"78","author":"Koivunen","year":"1999","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2021031813501280000_deab024-B25","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.fertnstert.2005.10.057","article-title":"Serum anti- m\u00fcllerian hormone levels in women with secondary amenorrhea","volume":"85","author":"La Marca","year":"2006","journal-title":"Fertil Steril"},{"key":"2021031813501280000_deab024-B26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejogrb.2015.01.007","article-title":"The role of anti-M\u00fcllerian hormone in the classification of anovulatory infertility","volume":"186","author":"Lie Fong","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2021031813501280000_deab024-B27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/09513590.2011.579664","article-title":"Serum anti-M\u00fcllerian hormone, inhibin B, and total inhibin levels in women with hypothalamic amenorrhea and anorexia nervosa","volume":"28","author":"Luisi","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"2021031813501280000_deab024-B28","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0003-4266(17)30923-X","article-title":"Control of the gonadotrope axis: new physiologic and therapeutic aspects","volume":"78","author":"Maione","year":"2017","journal-title":"Ann Endocrinol"},{"key":"2021031813501280000_deab024-B29","doi-asserted-by":"crossref","first-page":"e47198","DOI":"10.7554\/eLife.47198","article-title":"Defective AMH signaling disrupts GnRH neuron development and function and contributes to hypogonadotropic hypogonadism. In Elmquist JK, Dulac C, Elias CF, McNutt M, editors","volume":"8","author":"Malone","year":"2019","journal-title":"eLife"},{"key":"2021031813501280000_deab024-B31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.1999.00886.x","article-title":"Polycystic ovaries and associated clinical and biochemical features in young women","volume":"51","author":"Michelmore","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021031813501280000_deab024-B33","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.fertnstert.2009.07.1676","article-title":"Longitudinal assessment of antim\u00fcllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin","volume":"93","author":"Nelson","year":"2010","journal-title":"Fertil Steril"},{"key":"2021031813501280000_deab024-B34","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.fertnstert.2015.12.023","article-title":"Comparative assessment of five serum antim\u00fcllerian hormone assays for the diagnosis of polycystic ovary syndrome","volume":"105","author":"Pigny","year":"2016","journal-title":"Fertil Steril"},{"key":"2021031813501280000_deab024-B35","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0140-6736(88)91612-1","article-title":"Polycystic ovaries\u2013a common finding in normal women","volume":"331","author":"Polson","year":"1988","journal-title":"Lancet"},{"key":"2021031813501280000_deab024-B36","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1210\/jc.2012-1836","article-title":"Polycystic ovary-like abnormalities (PCO-L) in women with functional hypothalamic amenorrhea","volume":"97","author":"Robin","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021031813501280000_deab024-B37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"2021031813501280000_deab024-B38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/09513599609012819","article-title":"Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone","volume":"10","author":"Schachter","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"2021031813501280000_deab024-B39","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.fertnstert.2009.05.063","article-title":"Hypothalamic amenorrhea in young women with underlying polycystic ovary syndrome","volume":"92","author":"Sum","year":"2009","journal-title":"Fertil Steril"},{"key":"2021031813501280000_deab024-B40","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41591-018-0035-5","article-title":"Elevated prenatal anti- M\u00fcllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood","volume":"24","author":"Tata","year":"2018","journal-title":"Nat Med"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/4\/1043\/36638262\/deab024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/4\/1043\/36638262\/deab024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T08:28:44Z","timestamp":1698568124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/4\/1043\/6134554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,13]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,13]]},"published-print":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab024","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,2,13]]}}}